Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Accounts Payables (2016 - 2025)

Marimed (MRMD) has disclosed Accounts Payables for 15 consecutive years, with $11.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables fell 13.42% to $11.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.2 million, a 13.42% decrease, with the full-year FY2024 number at $13.2 million, up 46.53% from a year prior.
  • Accounts Payables was $11.2 million for Q3 2025 at Marimed, roughly flat from $11.2 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $14.0 million in Q1 2025 to a low of $4.7 million in Q1 2023.
  • A 5-year average of $9.0 million and a median of $8.3 million in 2022 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: crashed 43.87% in 2023, then soared 119.85% in 2024.
  • Marimed's Accounts Payables stood at $5.1 million in 2021, then rose by 29.95% to $6.6 million in 2022, then skyrocketed by 35.84% to $9.0 million in 2023, then skyrocketed by 46.53% to $13.2 million in 2024, then decreased by 14.77% to $11.2 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Accounts Payables are $11.2 million (Q3 2025), $11.2 million (Q2 2025), and $14.0 million (Q1 2025).